XRTX - XORTX Calls Special Meeting of Shareholders | Benzinga
CALGARY, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company has called a special meeting of shareholders for 10:00 a.m. (Calgary time) on October 25, 2023 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website.
The meeting has been called for shareholders to consider a consolidation of the Company's issued and outstanding shares in order for the Company to comply with continued listing requirements for the NASDAQ Capital Market.
Dr. Allen Davidoff, CEO and XORTX, stated, "NASDAQ is one of the premier public stock markets in the world and an overwhelming base of XORTX liquidity. Despite recent public market challenges, the Company remains committed to crystallizing the potential of our late stage clinical programs by continuing to remain on this important market. For this reason, management and the Board of Directors recommend voting in favor of the reverse split of XORTX shares to bring the Company once again into compliance with NASDAQ listing ...